Zhejiang Jolly Pharmaceutical Co Ltd

SHE:300181 China Drug Manufacturers - General
Market Cap
$1.58 Billion
CN¥11.59 Billion CNY
Market Cap Rank
#6600 Global
#1020 in China
Share Price
CN¥16.52
Change (1 day)
+0.67%
52-Week Range
CN¥15.59 - CN¥20.53
All Time High
CN¥20.53
Categories
Companies in China Drug Manufacturers - General
About

Zhejiang Jolly Pharmaceutical Co.,LTD engages in the research, production, and marketing of Chinese medicinal products in the People's Republic of China and internationally. It offers Wuling capsule to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kid… Read more

Zhejiang Jolly Pharmaceutical Co Ltd (300181) - Net Assets

Latest net assets as of September 2025: CN¥3.18 Billion CNY

Based on the latest financial reports, Zhejiang Jolly Pharmaceutical Co Ltd (300181) has net assets worth CN¥3.18 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.64 Billion) and total liabilities (CN¥1.46 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥3.18 Billion
% of Total Assets 68.54%
Annual Growth Rate 19.1%
5-Year Change 63.97%
10-Year Change 96.39%
Growth Volatility 53.83

Zhejiang Jolly Pharmaceutical Co Ltd - Net Assets Trend (2007–2024)

This chart illustrates how Zhejiang Jolly Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Zhejiang Jolly Pharmaceutical Co Ltd (2007–2024)

The table below shows the annual net assets of Zhejiang Jolly Pharmaceutical Co Ltd from 2007 to 2024.

Year Net Assets Change
2024-12-31 CN¥2.82 Billion +1.64%
2023-12-31 CN¥2.77 Billion +0.51%
2022-12-31 CN¥2.76 Billion +39.16%
2021-12-31 CN¥1.98 Billion +15.34%
2020-12-31 CN¥1.72 Billion +22.14%
2019-12-31 CN¥1.41 Billion +1.48%
2018-12-31 CN¥1.39 Billion -6.92%
2017-12-31 CN¥1.49 Billion +1.26%
2016-12-31 CN¥1.47 Billion +2.52%
2015-12-31 CN¥1.44 Billion +64.68%
2014-12-31 CN¥871.76 Million +12.85%
2013-12-31 CN¥772.52 Million +9.43%
2012-12-31 CN¥705.92 Million +3.22%
2011-12-31 CN¥683.92 Million +230.12%
2010-12-31 CN¥207.17 Million +25.03%
2009-12-31 CN¥165.70 Million +11.12%
2008-12-31 CN¥149.11 Million +3.21%
2007-12-31 CN¥144.47 Million --

Equity Component Analysis

This analysis shows how different components contribute to Zhejiang Jolly Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 5404.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥847.09 Million 30.59%
Common Stock CN¥701.39 Million 25.33%
Other Comprehensive Income CN¥296.61 Million 10.71%
Other Components CN¥923.80 Million 33.36%
Total Equity CN¥2.77 Billion 100.00%

Zhejiang Jolly Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Zhejiang Jolly Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
YAOKO CO. LTD
F:5FV
 		$1.19 Billion
Precision Drilling Corporation
NYSE:PDS
 		$1.19 Billion
LG Display Co Ltd
NYSE:LPL
 		$1.19 Billion
Trigano SA
LSE:0NX0
 		$1.19 Billion
Charter Hall Long WALE REIT
PINK:CHLWF
 		$1.19 Billion
Vaisala Oyj
PINK:VAIAF
 		$1.19 Billion
Ushio Inc
PINK:UHOIF
 		$1.19 Billion
Hyundai Mar&Fi
KO:001450
 		$1.19 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zhejiang Jolly Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,728,743,064 to 2,768,884,681, a change of 40,141,617 (1.5%).
  • Net income of 507,771,940 contributed positively to equity growth.
  • Dividend payments of 320,796,406 reduced retained earnings.
  • Share repurchases of 203,966,434 reduced equity.
  • Other comprehensive income increased equity by 253,942,445.
  • Other factors decreased equity by 196,809,928.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥507.77 Million +18.34%
Dividends Paid CN¥320.80 Million -11.59%
Share Repurchases CN¥203.97 Million -7.37%
Other Comprehensive Income CN¥253.94 Million +9.17%
Other Changes CN¥-196.81 Million -7.11%
Total Change CN¥- 1.47%

Book Value vs Market Value Analysis

This analysis compares Zhejiang Jolly Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.15x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 46.50x to 4.15x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2007-12-31 CN¥0.36 CN¥16.52 x
2008-12-31 CN¥0.37 CN¥16.52 x
2009-12-31 CN¥0.41 CN¥16.52 x
2010-12-31 CN¥0.51 CN¥16.52 x
2011-12-31 CN¥1.33 CN¥16.52 x
2012-12-31 CN¥1.31 CN¥16.52 x
2013-12-31 CN¥1.46 CN¥16.52 x
2014-12-31 CN¥1.48 CN¥16.52 x
2015-12-31 CN¥2.29 CN¥16.52 x
2016-12-31 CN¥2.20 CN¥16.52 x
2017-12-31 CN¥2.10 CN¥16.52 x
2018-12-31 CN¥2.12 CN¥16.52 x
2019-12-31 CN¥2.15 CN¥16.52 x
2020-12-31 CN¥2.63 CN¥16.52 x
2021-12-31 CN¥3.03 CN¥16.52 x
2022-12-31 CN¥3.85 CN¥16.52 x
2023-12-31 CN¥3.92 CN¥16.52 x
2024-12-31 CN¥3.98 CN¥16.52 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zhejiang Jolly Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 18.34%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 19.70%
  • • Asset Turnover: 0.65x
  • • Equity Multiplier: 1.44x
  • Recent ROE (18.34%) is above the historical average (9.78%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2007 9.62% 10.98% 0.50x 1.74x CN¥-552.65K
2008 11.16% 10.09% 0.59x 1.88x CN¥1.73 Million
2009 19.06% 14.67% 0.72x 1.80x CN¥15.01 Million
2010 20.02% 15.79% 0.75x 1.68x CN¥20.76 Million
2011 7.45% 18.23% 0.33x 1.23x CN¥-17.46 Million
2012 8.78% 18.04% 0.40x 1.22x CN¥-8.59 Million
2013 10.48% 19.31% 0.45x 1.22x CN¥3.75 Million
2014 12.84% 20.04% 0.44x 1.47x CN¥22.81 Million
2015 6.56% 12.64% 0.36x 1.43x CN¥-44.40 Million
2016 5.45% 8.57% 0.41x 1.54x CN¥-60.15 Million
2017 3.33% 6.65% 0.32x 1.59x CN¥-90.33 Million
2018 1.61% 2.84% 0.35x 1.64x CN¥-108.40 Million
2019 1.95% 2.81% 0.44x 1.56x CN¥-105.44 Million
2020 5.54% 8.14% 0.44x 1.54x CN¥-71.48 Million
2021 9.73% 12.31% 0.53x 1.49x CN¥-5.00 Million
2022 10.10% 15.12% 0.50x 1.35x CN¥2.63 Million
2023 14.03% 19.71% 0.54x 1.33x CN¥110.06 Million
2024 18.34% 19.70% 0.65x 1.44x CN¥230.88 Million

Industry Comparison

This section compares Zhejiang Jolly Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

  • Industry: Drug Manufacturers - General
  • Average net assets among peers: $727,935,986
  • Average return on equity (ROE) among peers: 7.94%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Zhejiang Jolly Pharmaceutical Co Ltd (300181) CN¥3.18 Billion 9.62% 0.46x $1.19 Billion
Zhejiang Int'L Group Co Ltd (000411) $189.44 Million 3.08% 4.33x $199.04 Million
Zhejiang Zhenyuan Share Co Ltd (000705) $485.74 Million 1.60% 0.77x $307.06 Million
Hunan Jingfeng Pharmaceutical (000908) $336.40 Million 0.81% 1.44x $202.85 Million
Hubei Guangji Pharmaceutical Co Ltd (000952) $1.49 Billion 3.37% 0.66x $229.65 Million
Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) $1.25 Billion 8.38% 0.07x $144.69 Million
Yifan Xinfu Pharmaceutical Co Ltd (002019) $507.64 Million 23.17% 1.09x $1.01 Billion
Guangdong Jiaying Pharmaceutical Co Ltd (002198) $226.35 Million 6.06% 0.04x $447.60 Million
Chongqing Lummy Pharmaceutical (300006) $1.88 Billion -4.66% 0.52x $475.43 Million
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) $181.38 Million 29.65% 0.05x $893.83 Million